Saskia Litière

12.3k citations

103 papers · 6.7k indexed · 4 hit papers · h-index 32

Oncology top 0.5%
- Vascular Tumors and Angiosarcomas 26
Pulmonary and Respiratory Medicine top 0.5%
- Sarcoma Diagnosis and Treatment 50
- Lung Cancer Treatments and Mutations 10
Cancer Research top 1%
- Cancer Genomics and Diagnostics 19
- Breast Cancer Treatment Studies 14
Pathology and Forensic Medicine top 1%
- Lymphoma Diagnosis and Treatment 9
Cardiology and Cardiovascular Medicine top 2%
- Cardiac tumors and thrombi 18
Statistics and Probability
- Statistical Methods in Clinical Trials 8

Co-authors: Jan Bogaerts Lesley Seymour Elisabeth G.E. de Vries Lalitha Shankar Patrick Therasse Sumithra J. Mandrekar Janet Dancey Otto S. Hoekstra
Cited by: Oncology Pulmonary and Respiratory Medicine Cancer Research
Partner nations: Belgium Netherlands France

In The Last Decade

Saskia Litière

96 papers receiving 6.6k citations

Hit Papers

align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2017 iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
2016 RECIST 1.1—Update and clarification: From the RECIST committee
2014 Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
2012 Breast conserving therapy versus mastectomy for stage I–II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial

Peers

Countries citing papers authored by Saskia Litière

Since Specialization

Citations

This map shows the geographic impact of Saskia Litière's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Saskia Litière with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Saskia Litière more than expected).

Fields of papers citing papers by Saskia Litière

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Saskia Litière. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Saskia Litière. The network helps show where Saskia Litière may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Saskia Litière, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Saskia Litière Line = papers co-authored together Saskia Litière links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	CINSARC and Sarculator in Patients with Primary Retroperitoneal Sarcoma: A Combined Analysis of Single-Institution Data and the EORTC-STBSG-62092 Trial (STRASS) Dario Callegaro,Gabriele Tinè,Felix Boakye Oppong,Axelle Nzokirantevye,Saskia Litière,Stefano Percio,Andrea Carenzo,Loris De Cecco,Frédéric Chibon,Silvia Brich,Alessia Bertolotti,Paola Collini,Anna Maria Frezza,Paul H. Huang,Rick L. Haas,Sylvie Bonvalot,Winan J. van Houdt,Rosalba Miceli,Sandro Pasquali,Alessandro Gronchi	2025	0
2	Kidney function assessment for eligibility in clinical cancer trials – Data from the European Organisation for Research and Treatment of Cancer H.C. Puhr,Eleni Xenophontos,Antoine Giraud,Saskia Litière,Luc Boone,Jan Bogaerts,Maike Collienne,Matthias Preusser	2024	0
3	Tumor Size Is Not Everything: Advancing Radiomics as a Precision Medicine Biomarker in Oncology Drug Development and Clinical Care. A Report of a Multidisciplinary Workshop Coordinated by the RECIST Working Group Erica C. Nakajima,Amber L. Simpson,Jan Bogaerts,Elisabeth G.E. de Vries,Richard Kinh Gian,Elena Garralda,Gregory Goldmacher,Paul E. Kinahan,Philippe Lambin,Barbara LeStage,Qin Li,Frank Lin,Saskia Litière,Raquel Pérez-López,Nicholas Petrick,Lawrence H. Schwartz,Lesley Seymour,Lalitha Shankar,Scott A. Laurie	2024	3
4	Attitudes of healthcare professionals and drug regulators about progression-free survival as endpoint in the advanced cancer setting Douwe Postmus,Saskia Litière,Jan Bogaerts,Jurjen Versluis,Jan J. Cornelissen,Francesco Pignatti	2023	3
5	MRI Apparent Diffusion Coefficient (ADC) as a Biomarker of Tumour Response: Imaging-Pathology Correlation in Patients with Hepatic Metastases from Colorectal Cancer (EORTC 1423) Alan Jackson,Ryan Pathak,Nandita M. deSouza,Yan Liu,Bart K. M. Jacobs,Saskia Litière,Maria Urbanowicz-Nijaki,Catherine Julié,Arturo Chiti,Jens Theysohn,Juan Ramón Ayuso,Sigrid Stroobants,John C. Waterton	2023	2
6	Meta-Analysis of the Test–Retest Repeatability of [18F]-Fluorodeoxyglucose Standardized Uptake Values: Implications for Assessment of Tumor Response Lalitha Shankar,Erich P. Huang,Saskia Litière,Otto S. Hoekstra,Lawrence H. Schwartz,Sandra Collette,Ronald Boellaard,Jan Bogaerts,Lesley Seymour,Elisabeth G.E. de Vries	2022	3
7	New benchmarks to design clinical trials with advanced or metastatic liposarcoma or synovial sarcoma patients: An EORTC – Soft Tissue and Bone Sarcoma Group (STBSG) meta-analysis based on a literature review for soft-tissue sarcomas Georgios Kantidakis,Saskia Litière,Anouk Neven,Marie Vinches,Ian Judson,Jean‐Yves Blay,Eva Wardelmann,Silvia Stacchiotti,Lorenzo D’Ambrosio,Sandrine Marréaud,Winette T.A. van der Graaf,Bernd Kasper,Marta Fiocco,Hans Gelderblom	2022	7
8	Exploratory analysis of tumor imaging in a Phase 2 trial with cabozantinib in gastrointestinal stromal tumor: lessons learned from study EORTC STBSG 1317 ‘CaboGIST’ Anastasios Kyriazoglou,Pieter Jespers,Vincent Vandecavaye,Olivier Mir,Bernd Kasper,Zsuzsanna Pápai,Jean‐Yves Blay,Antoîne Italiano,Facundo Zaffaroni,Saskia Litière,Axelle Nzokirantevye,Patrick Schöffski	2022	1
9	Randomised phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy: EORTC-1506-STBSG “ANITA” Patrick Schöffski,Maud Toulmonde,Anna Estival,Gloria Marquina,Monika Dudzisz‐Śledź,Mehdi Brahmi,Neeltje Steeghs,Vasilios Karavasilis,Jacco J. de Haan,Agnieszka Woźniak,Sophie Cousin,Marta Doménech,Judith V.M.G. Bovée,Céline Charon‐Barra,Sandrine Marréaud,Saskia Litière,Laura De Meulemeester,Christine Olungu,Hans Gelderblom	2021	10
10	Efficacy thresholds for clinical trials with advanced or metastatic leiomyosarcoma patients: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group meta-analysis based on a literature review for soft-tissue sarcomas Georgios Kantidakis,Saskia Litière,Anouk Neven,Marie Vinches,Ian Judson,Patrick Schöffski,Eva Wardelmann,Silvia Stacchiotti,Lorenzo D’Ambrosio,Sandrine Marréaud,Winette T.A. van der Graaf,Bernd Kasper,Marta Fiocco,Hans Gelderblom	2021	7
11	Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre study Anastasia Constantinidou,Nicolas Sauvé,Silvia Stacchiotti,Jean‐Yves Blay,Bruno Vincenzi,Giovanni Grignani,Piotr Rutkowski,Michele Guida,Nadia Hindi,Alexander Klein,Thibaud Valentin,Jozef Šufliarský,Ingrid M.E. Desar,Neeltje Steeghs,Saskia Litière,Hans Gelderblom,Robin L. Jones	2020	26
12	Impact of Concomitant Administration of Gastric Acid–Suppressive Agents and Pazopanib on Outcomes in Soft-Tissue Sarcoma Patients Treated within the EORTC 62043/62072 Trials Olivier Mir,Nathan Touati,Michela Lia,Saskia Litière,Axel Le Cesne,Stefan Sleijfer,Jean‐Yves Blay,Michael Leahy,Robin Young,Ron H.J. Mathijssen,Nielka P. van Erp,Hans Gelderblom,Winette T.A. van der Graaf,Alessandro Gronchi	2019	64
13	Prospective assessment of the predictive value of the BRCA1 gene status in sarcoma patients treated with trabectedin: an updated analysis of the EORTC 62091 trial Antoîne Italiano,Nathan Touati,Saskia Litière,Françoise Collin,Philippe Pourquier,Alessandro Gronchi	2018	7
14	Characterisation of multifocal breast cancer using the 70-gene signature in clinical low-risk patients enrolled in the EORTC 10041/BIG 03-04 MINDACT trial K.C. Aalders,Anne Kuijer,Marieke E. Straver,Leen Slaets,Saskia Litière,Giuseppe Viale,Laura J. van’t Veer,Annuska M. Glas,Mauro Delorenzi,Thijs van Dalen,Konstantinos Tryfonidis,Martine Piccart,Fátima Cardoso,Emiel J. Rutgers	2017	10
15	Investigating the heterogeneity of alkylating agents’ efficacy and toxicity between sexes: A systematic review and meta‐analysis of randomized trials comparing cyclophosphamide and ifosfamide (MAIAGE study) Brice Fresneau,Allan Hackshaw,Douglas S. Hawkins,Michael Paulussen,J R Anderson,Ian Judson,Saskia Litière,Uta Dirksen,I J Lewis,Henk van den Berg,Nathalie Gaspar,Hans Gelderblom,Jeremy Whelan,Alan V. Boddy,K. Wheatley,Jean‐Pierre Pignon,Florent de Vathaire,Marie‐Cécile Le Deley,Gwénaël Le Teuff	2017	7
16	Time to definitive failure to the first tyrosine kinase inhibitor in localized gastrointestinal stromal tumors (GIST) treated with imatinib as an adjuvant: Final results of the EORTC STBSG, AGITG, UNICANCER, FSG, ISG, and GEIS randomized trial Paolo G. Casali,Axel Le Cesne,Andrés Poveda,Dusan Kotasek,Piotr Rutkowski,Peter Hohenberger,Elena Fumagalli,Ian Judson,Antoîne Italiano,Hans Gelderblom,Nicolas Penel,H-G. Kopp,David Goldstein,Javier Martín‐Broto,Alessandro Gronchi,Eva Wardelmann,Sandrine Marréaud,John Zalcberg,Saskia Litière,Jean‐Yves Blay	2017	0
17	RECIST 1.1—Update and clarification: From the RECIST committeebreakdown → Lawrence H. Schwartz,Saskia Litière,Elisabeth G.E. de Vries,Robert Ford,Stephen J. Gwyther,Sumithra J. Mandrekar,Lalitha Shankar,Jan Bogaerts,Alice P. Chen,Janet Dancey,Wendy Hayes,F. Stephen Hodi,Otto S. Hoekstra,Erich P. Huang,Nancy U. Lin,Yan Liu,Patrick Therasse,Jedd D. Wolchok,Lesley Seymour	2016	1206
18	Pazopanib in advanced desmoplastic small round cell tumours: a multi-institutional experience Anna Maria Frezza,Charlotte Benson,Ian Judson,Saskia Litière,Sandrine Marréaud,Stefan Sleijfer,Jean‐Yves Blay,R. Dewji,Cyril Fisher,Winette van der Graaf,Larry Hayward	2014	41
19	Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials Axel Le Cesne,M. Ouali,Michael Leahy,Armando Santoro,Harald J. Hoekstra,Peter Hohenberger,Frits van Coevorden,Piotr Rutkowski,René van Hoesel,Jaap Verweij,Sylvie Bonvalot,William P. Steward,Alessandro Gronchi,Pancras C.W. Hogendoorn,Saskia Litière,Sandrine Marréaud,Jean‐Yves Blay,Winette T.A. van der Graaf	2014	118
20	Rejoinder to “A Note on Type II Error Under Random Effects Misspecification in Generalized Linear Mixed Models” Saskia Litière,Ariel Alonso,Geert Molenberghs	2010	1

About Saskia Litière

Saskia Litière is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Oncology, having authored 103 papers that have together received 6.7k indexed citations. Recurring topics across this work include Sarcoma Diagnosis and Treatment (50 papers), Vascular Tumors and Angiosarcomas (26 papers), Cancer Genomics and Diagnostics (19 papers), Cardiac tumors and thrombi (18 papers), Breast Cancer Treatment Studies (14 papers), Lung Cancer Treatments and Mutations (10 papers), Lymphoma Diagnosis and Treatment (9 papers) and Statistical Methods in Clinical Trials (8 papers). The work is most often cited by research in Oncology (4.0k citations), Pulmonary and Respiratory Medicine (3.3k citations) and Cancer Research (1.4k citations). Saskia Litière has collaborated with scholars based in Belgium, Netherlands and France. Frequent co-authors include Jan Bogaerts, Lesley Seymour, Elisabeth G.E. de Vries, Lalitha Shankar, Patrick Therasse, Sumithra J. Mandrekar, Janet Dancey, Otto S. Hoekstra, Nancy U. Lin and Lawrence H. Schwartz.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact